A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.
Also called NCT02932410
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 165 participants
- Sponsor
- Registry
-
NCT02932410
-
- Other papers using this trial's data
- Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Brazil, Canada, China, Colombia, Finland, France, Hungary, Israel, Malaysia, Mexico, Philippines, Poland, Portugal, Russia, South Africa, South Korea, Spain, Thailand, Ukraine, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT02932410. Randomized; no masking; primary purpose treatment. Start 2017-10-24 (actual); primary completion 2024-08-28 (actual). Results posted on 2025-09-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
- Acronym
- TOMORROW
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Macitentan
- Intervention (Other)
- Standard-of-care
- Lead sponsor
- Actelion
Record details
- Record id
cardio:ct-nct02932410- Content hash
b770bc7632d9374233101c2a3b624f5dfef776768f40c8aa62b6a6debd6f931a